Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06122467
Other study ID # 20365
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2, 2023
Est. completion date December 31, 2023

Study information

Verified date March 2024
Source Menning Labs
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This twelve-week trial will examine the effectiveness of a Menning Labs EQ Product Line acne product. Participants will use the exfoliating cleanser, cream, and gel daily for 8 weeks. Participants will complete questionnaires at Baseline, Day 1, Day 3, Day 7, Day 28, Day 42, and Day 56. Participants will also provide before-and-after photos at Baseline, Day 7, and Day 42, as well as undergo expert skin grading at Baseline and Day 42. The questionnaire on Day 56 will mark the conclusion of the trial.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Be aged between 18-45. - Anyone who has acne prone skin and a history of recurring acne. - Has visible acne at enrollment. - Anyone who is generally healthy - does not live with any uncontrolled chronic disease. - Have a digital camera or smartphone to take photos of the face. Exclusion Criteria: - Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. - Anyone currently using a prescription skin product. - Anyone who is unwilling to stop using the current acne supplements they are taking. - Anyone with known severe allergic reactions. - Any women who are pregnant, breastfeeding or attempting to become pregnant. - Anyone unwilling to follow the study protocol. - Anyone who identifies as having sensitive skin.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
EQ Exfoliating Cleanser
Product contains: Purified water, disodium laureth sulfosuccinate, coco betaine, decyl glucoside, Juglans regia (walnut) shells, PEG-40 hydrogenated castor oil, sodium cocoyl isethionate disodium cocoyl glutamate, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), Aloe barbadensis (aloe vera) leaf juice concentrate (Aloe barbadensis leaf juice, potassium sorbate, sodium benzoate, citric acid).
EQ Gel
Product contains: Purified water, witch hazel (containing 14% grain alcohol), PEG-40 hydrogenated castor oil, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), xanthan gum.
EQ Moisturizer
Product contains: Purified water, glycerin, dicaprylyl carbonate, cetyl alcohol, glyceryl stearate citrate, squalane, PEG-40 hydrogenated castor oil, caprylic/capric triglycerides, stearic acid, jojoba oil, phenoxyethanol SA (phenoxyethanol, caprylyl glycol, sorbic acid), ethoxydiglycol, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), allantoin, sodium carbomer.

Locations

Country Name City State
United States Citruslabs Santa Monica California

Sponsors (2)

Lead Sponsor Collaborator
Menning Labs Citruslabs

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the appearance of facial skin acne. [Timeframe: Baseline to Day 56] Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.
Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.
56 days
Primary Changes in skin clarity i.e. reduction in acne or associated blemishes. [Timeframe: Baseline to Day 56] Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.
Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.
56 days
Secondary Changes in overall skin health. [Timeframe: Baseline to Day 56] Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.
Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.
56 days
Secondary Changes in skin texture. [Timeframe: Baseline to Day 56] Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.
Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.
56 days
Secondary Changes in facial skin irritation. [Timeframe: Baseline to Day 56] Surveys will be completed independently by study participants. Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). 56 days
Secondary Changes in skin redness. [Timeframe: Baseline to Day 56] Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.
Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.
56 days
Secondary Changes in skin smoothness. [Timeframe: Baseline to Day 56] Assessed by surveys completed independently by study participants. Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). 56 days
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT04806594 - Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar. N/A
Recruiting NCT03465150 - Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
Completed NCT02250859 - A Pharmacokinetic Study of Minocycline in Male and Female Volunteers Phase 1
Completed NCT01206348 - Combination Treatment for Moderate to Severe Acne Phase 4
Terminated NCT01193764 - Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris N/A
Completed NCT00725439 - An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne Phase 2
Completed NCT05640388 - Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
Completed NCT04873089 - Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
Recruiting NCT05941065 - Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin N/A
Recruiting NCT06120452 - A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation N/A
Completed NCT04300010 - Blue Light Therapy of C. Acnes Phase 4
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Completed NCT04559022 - Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring N/A
Terminated NCT02431494 - Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris N/A
Completed NCT05469880 - Efficacy and Tolerance of Formula 609613 37 in Acneic Patients N/A
Completed NCT02944461 - Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Phase 4
Completed NCT01951417 - Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Phase 4
Completed NCT01701024 - Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne Phase 3